Introduction
MAP-AD® is a non-invasive blood test designed to support the early detection and management of Alzheimer’s Disease(AD) in patients with Mild Cognitive Impairment (MCI).
The test combines multiple biological and clinical data layers within an advanced multi-class Artificial Intelligence (AI) framework, providing an integrated approach to diagnostic and prognostic assessment.
Rather than relying on a single biomarker or biological dimension, MAP-AD® evaluates multiple sources of information simultaneously. By integrating systemic biological signals with clinically relevant data, the test provides a more comprehensive view of the patient and supports informed clinical decision-making.
Key Features
- Non-invasive blood-based testing
- Designed for patients with Mild Cognitive Impairment (MCI)
- Supports early detection and disease management
- Integrates multiple biological and clinical data layers
- Uses a multi-class AI framework
- Designed to enhance diagnostic and prognostic assessment
- Connects systemic biology with clinical practice
